Expression of Angiogenic Inhibitors in Benign Prostate Hyperplasia and Prostate Cancer

Zhong-han YANG,Chao-yang LI,Xia YANG,Wei-bin CAI,Qing-song WANG,Shi-hao ZHOU,Chun-hua DENG,Guo-quan GAO,Shao-peng QIU

DOI: https://doi.org/10.3321/j.issn:1672-3554.2006.02.002

2006-01-01

Abstract:[Objective] To evaluate the expression of angiogenic inhibitors such as pigment epithelium-derived factor(PEDF), angiostatin, and endostatin in benign prostate hyperplasia (BPH) and prostate cancer (PCa) and to discuss the molecular mechanism of angiogenic-dependent growth in BPH and prostate cancer. [Methods] Reverse transcriptase-polymerase chain reaction (RT-PCR) was used for detecting PEDF, angiostatin, and endostatin mRNA levels in the specimens from normal prostate (n = 5), BPH (n = 5), and prostate cancer (n = 5) tissues. Western blot analysis was used for detecting PEDF protein levels in the specimens. [Results] mRNA level of PEDF decreased in PCa tissues (P< 0.05) compared with normal prostate tissues. There was no significant difference between normal and BPH tissues (P >0.05). mRNA level of endostatin was higher in BPH tissues than in the normal tissues(P< 0.05), and even higher in PCa tissues (P< 0.05). It was also higher in PCa tissues than in the BPH tissues (P< 0.05). Angiostatin mRNA level was not detected in all tissues. [Conclusions] The expression of angiogenic inhibitors in the BPH and PCa tissues may be correlated with their angiogenic-dependent growth, and PEDF may be the most dominent anti-angiogenic inhibitor in prostate tissues.